Analysts Offer Insights on Healthcare Companies: Strongbridge Biopharma Plc (NASDAQ: SBBP), Aurinia Pharmaceuticals (NASDAQ: AUPH) and NovaBay Pharma (NYSE: NBY)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Strongbridge Biopharma Plc (NASDAQ: SBBP), Aurinia Pharmaceuticals (NASDAQ: AUPH) and NovaBay Pharma (NYSE: NBY) with bullish sentiments.

Strongbridge Biopharma Plc (NASDAQ: SBBP)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Strongbridge Biopharma Plc (NASDAQ: SBBP) today and set a price target of $18. The company’s shares closed yesterday at $5.75.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.7% and a 47.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Strongbridge Biopharma Plc has an analyst consensus of Moderate Buy, with a price target consensus of $18.

Aurinia Pharmaceuticals (NASDAQ: AUPH)

H.C. Wainwright analyst Ed Arce assigned a Buy rating to Aurinia Pharmaceuticals (NASDAQ: AUPH) today and set a price target of $12. The company’s shares closed yesterday at $5.34.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 19.9% and a 43.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics Inc, and Collegium Pharmaceutical.

Aurinia Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $11.63.

NovaBay Pharma (NYSE: NBY)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on NovaBay Pharma (NYSE: NBY), with a price target of $6. The company’s shares closed yesterday at $4.45.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -13.3% and a 28.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as RegeneRx Biopharmaceuticals Inc, Biospecifics Technologies Corp, and Synergy Pharmaceuticals Inc.

NovaBay Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.